A missing gene may help explain a hard to treat brain tumor
Original title: Chromosome 6q mediated loss of LATS1 tumour suppression as a targetable mechanism of ultra-high-risk posterior fossa A ependymoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
The drugs were only tested on cells in a dish, not in people.
The short version
A missing gene may explain why this brain tumor is so hard to treat.
What was studied. Researchers studied a brain tumor called PFA ependymoma. They looked at new and returning tumors, and tested tumor cells in the lab.
What they found. Tumors missing part of chromosome 6q had also lost a gene called LATS1, which helps hold cell growth in check. Putting that gene back into tumor cells in the lab slowed their growth. Loss of 6q was linked to nearly half of the deaths from this tumor.
What this means, and what it doesn't
What it could mean: This gives scientists a clear target to aim at. Two lab drugs built for that target harmed these tumor cells. That is a useful starting point for more research.
What it doesn't mean: This does not mean there is a new treatment. The work was done on tumor samples and on cells in a dish. No patient was treated with these drugs. They have not been tested in people at all. This is early lab science, not a cure, and not something a doctor can offer today.
Source: PubMed, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.